Menu

Cannabis-Based Drug for Epilepsy

A marijuana-derived compound shows continued success in treating children with a rare form of the seizure disorder. 

Mar 14, 2016
Jef Akst

FLICKR, BOB DORANLondon-based GW Pharmaceuticals announced today (March 14) that its cannabis-based drug Epidiolex significantly reduced seizures in children with Dravet syndrome, a rare and severe form of epilepsy, in the first of four large trials of the treatment. Specifically, patients taking the drug experienced 39 percent fewer seizures, compared with a 13 percent reduction in the control group.

“This shows that cannabinoids can produce compelling and clinical [sic] important data and represent a highly promising new class of medications, hopefully in a range of conditions,” GW’s chief executive, Justin Gover, told Reuters. The company, which is currently conducting three other Phase 3 trials for patients with Dravet and other rare forms of epilepsy, plans to move forward with its application for US Food and Drug Administration approval. Epidiolex—which is made of cannabidiol, a component of marijuana that does not cause psychoactive effects—would be the first marijuana-based prescription drug marketed in the U.S., The New York Times reported; two synthetic versions of THC, the component of marijuana that does make people feel “high,” are already on the US market (to quell nausea in patients undergoing cancer chemotherapy and to treat weight and appetite loss in patients with AIDS).

(For more on GW Pharmaceuticals and other biotech companies looking to bring cannabis-based drugs through clinical trials, see “Cannabis Biotech,” The Scientist, December 2014.)

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening